{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.89","upperLimit":"78.02","value":"68.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Best response (complete response or complete remission with partial platelet recovery) after up to 2 cycles of therapy, where response is assessed using the revised Acute Myeloid Leukemia International Working Group Criteria. Percentage of responders is calculated using the methods of Jung and Kim. 90% confidence interval is determined using the methods of Koyama and Chen.","dispersionType":"90% Confidence Interval","groups":[{"description":"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.\n\nCOURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5.","id":"OG000","title":"Treatment (CPX-351 and FLAG)"}],"paramType":"NUMBER","populationDescription":"1 patient among the 38 eligible patients was not evaluable for response.","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks","title":"Percentage of Responders (Complete Response or Complete Remission With Partial Platelet Recovery) After up to 2 Cycles","type":"PRIMARY","unitOfMeasure":"Percantage of best responders"}